In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 65 for your search:

Drug:  letrozole
Find trials that include:  Any drugs shown
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Aromatase Inhibitor Clinical Trial

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 40 to 70
Sponsor: NIGMS
Protocol IDs: 0412-14, UO1-GM61373-06, NCT00228956

Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women

Phase: Phase IV
Type: Treatment
Status: Active
Age: Postmenopausal
Sponsor: Other
Protocol IDs: KBCSG006, NCT01069211

Pharmacology of Adjuvant Hormonotherapy in Breast Cancer

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09 SEIN 09, NCT01127295

Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001JIL05, NCT01231659

Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11 SEIN 09, NCT01553903

Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11SEIN12, NCT01612871

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 65 and over
Sponsor: Other
Protocol IDs: 0120070323, NCT00698971

Phase III Randomized Study of Letrozole With or Without Lapatinib Ditosylate in Postmenopausal Women With Stage IV Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GSK-EGF30008, UCLA-0311034-01, NCT00073528

Assessing Impact of Loco-regional Treatment on Survival in Metastatic Breast Cancer at Presentation

Phase: Phase III
Type: Treatment
Status: Active
Age: 21 to 65
Sponsor: Other
Protocol IDs: TMH/153/2004, NCT00193778

10.

Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial)

Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: ECOG-PACCT-1, PACCT-1, NCT00310180

11.

Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000526522, EORTC-10041, EUDRACT-2005-002625-31, BIG-3-04, EU-20676, NOVARTIS-EORTC-10041, ROCHE-EORTC-10041, SANOFI-AVENTIS-EORTC-10041, NCT00433589

12.

HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.

Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HOBOE, NCT00412022

13.

Phase III Randomized Study of Adjuvant Therapy Comprising Tamoxifen Citrate Followed By Either Anastrozole, Letrozole, or Exemestane Versus Anastrozole, Letrozole, or Exemestane Alone in Postmenopausal Women With Resected Endocrine-Responsive Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: GIM-3-FATA, GIM3-FATA, EUDRACT-2006-004018-42, EU-20764, NCT00541086

14.

Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation

Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 40 to 69
Sponsor: Other
Protocol IDs: UC-0104/0701 - ONCO03, ONCO-03/0701, EU-20806, NOVARTIS-FNCLCC-ONCO 03/0701, 2007-000687-24, FNCLCC-ONCO-03/0701, FNCLCC-ONCO 03/0701 - LIBER, NCT00673335

15.

Phase III Randomized Study of Fulvestrant With or Without Lapatinib Tosylate and/or Aromatase Inhibitor Therapy in Postmenopausal Women With Metastatic Breast Cancer That Progressed After Prior Aromatase Inhibitor Therapy

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GIM-GIM8-OVER, GIM8-OVER, EUDRACT-2007-006031-30, EU-20853, GSK-GIM-GIM8-OVER, ZENECA-GIM-GIM8-OVER, OVER, NCT00688194

16.

Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: CDR0000635986, COL-MNEMOSYNE, 2007-12, INCA-RECF0899, EUDRACT-2008-003620-32, MNEMOSYNE, NCT00893061

17.

Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 65 and over
Sponsor: Other
Protocol IDs: CDR0000638373, CLCC-LETROTAM, VA 2007/09, INCA-RECF0916, EUDRACT-2007-000900-34, LETROTAM, NCT00949598

18.

Phase III Pilot Randomized Study of Neoadjuvant Chemotherapy Versus Aromatase Inhibition in Postmenopausal Patients With Operable Estrogen Receptor-Positive Primary Breast Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Postmenopausal; 18-70 years old
Sponsor: Other
Protocol IDs: ICCRU-NEOcent-C-21-07, NEOcent, ICCRU-NEOcent-C-21-07, EU-20936, EUDRACT-2006-003596-12, ISRCTN77234840, NCT00963729

19.

Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: Postmenopausal
Sponsor: Other
Protocol IDs: SHBCC0701, NCT00902954

20.

Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: DBCG 07-REAL, NCT00908531

21.

Letrozole as a Treatment of Endometrial Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 40 and over
Sponsor: Other
Protocol IDs: 200917341, CFEM 345AUS63, NCT00997373

22.

Phase III Randomized Study of Standard Versus Long Treatment With Adjuvant Letrozole in Post-Menopausal Women With Stage I-III Breast Cancer Previously Treated With Tamoxifen

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GIM-4-LEAD, GIM-4-LEAD, EUDRACT-2005-001212-44, EU-21003, NCT01064635

23.

Phase III Randomized Study of Standard Adjuvant Endocrine Therapy With Versus Without Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive, and HER2-Negative Breast Cancer

Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S1007, S1007, NCT01272037

24.

Phase III Randomized Study of Acupuncture Versus Sham Acupuncture Versus Waiting List for Joint Symptoms Related to Aromatase Inhibitors in Patients With Stage I-III Breast Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Status: Approved-not yet active
Age: Postmenopausal
Sponsor: NCI
Protocol IDs: SWOG-S1200, S1200, NCT01535066

25.

Phase III Randomized Study of Testosterone in Postmenopausal Patients With Arthralgia Induced by Adjuvant Aromatase Inhibitor Treatment

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N10C7, N10C7, NCT01573442

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map

Other Versions of this Site: Mobile | Español

Follow Us:

Twitter
YouTube
Facebook
RSS

NIH…Turning Discovery Into Health^®